Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide is a research paper published in Frontiers in Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 10 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIGMS NIH HHS
Grant: R35 GM133658
National Institutes of Health
Grant: 5R35GM133658-02
Network-based Framework to Decode Novel âÃÂÃÂGain-of-FunctionâÃÂàMutations and their Mechanistic Roles in General Human Diseases
National Institutes of Health
Grant: 4R01FD004400-02
Phase 2 Study of TH-302 for the Treatment of Glioblastoma
U.S. Food and Drug Administration
FWCI
0.67
Citation Percentile
0.6%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals